Education
About Us
Working with TipRanks
Follow Us
Capricor Therapeutics (CAPR)
NASDAQ:CAPR
Total Valuation
Capricor Therapeutics has a market cap or net worth of $541.73M. The enterprise value is $467.54M.
Market Cap$541.73M
Enterprise Value$467.54M
Share Statistics
Capricor Therapeutics has 45,676,888 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding45,676,888
Owned by Insiders16.81%
Owned by Institutions0.04%
Financial Efficiency
Capricor Therapeutics’s return on equity (ROE) is -0.28 and return on invested capital (ROIC) is -28.32%.
Return on Equity (ROE)-0.28
Return on Assets (ROA)-0.24
Return on Invested Capital (ROIC)-28.32%
Return on Capital Employed (ROCE)-0.28
Revenue Per Employee139.19K
Profits Per Employee-252.92K
Employee Count160
Asset Turnover0.13
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Capricor Therapeutics is -12.01. Capricor Therapeutics’s PEG ratio is -0.31.
PE Ratio-12.01
PS Ratio0.00
PB Ratio3.34
Price to Fair Value3.34
Price to FCF-11.70
Price to Operating Cash Flow-12.15
PEG Ratio-0.31
Income Statement
In the last 12 months, Capricor Therapeutics had revenue of 22.27M and earned -40.47M in profits. Earnings per share was -1.15.
Revenue22.27M
Gross Profit-27.70M
Operating Income-42.56M
Pretax Income-40.47M
Net Income-40.47M
EBITDA-41.17M
Earnings Per Share (EPS)-1.15
Cash Flow
In the last 12 months, operating cash flow was -40.00M and capital expenditures -1.54M, giving a free cash flow of -41.53M billion.
Operating Cash Flow-40.00M
Free Cash Flow-41.53M
Free Cash Flow per Share-0.91
Dividends & Yields
Capricor Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.57
52-Week Price Change31.51%
50-Day Moving Average11.59
200-Day Moving Average12.41
Relative Strength Index (RSI)29.15
Average Volume (3m)1.43M
Important Dates
Capricor Therapeutics upcoming earnings date is May 13, 2025, TBA Not Confirmed.
Last Earnings DateMar 19, 2025
Next Earnings DateMay 13, 2025
Ex-Dividend Date―
Financial Position
Capricor Therapeutics as a current ratio of 8.09, with Debt / Equity ratio of 2.13%
Current Ratio8.09
Quick Ratio8.09
Debt to Market Cap0.00
Net Debt to EBITDA-0.04
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Capricor Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Capricor Therapeutics EV to EBITDA ratio is -11.84, with an EV/FCF ratio of -11.74.
EV to Sales21.89
EV to EBITDA-11.84
EV to Free Cash Flow-11.74
EV to Operating Cash Flow-12.19
Balance Sheet
Capricor Therapeutics has $85.03M in cash and marketable securities with ― in debt, giving a net cash position of -$83.58M billion.
Cash & Marketable Securities$85.03M
Total Debt―
Net Cash-$83.58M
Net Cash Per Share-$1.83
Tangible Book Value Per Share$4.13
Margins
Gross margin is 31.55%, with operating margin of -191.13%, and net profit margin of -181.71%.
Gross Margin31.55%
Operating Margin-191.13%
Pretax Margin-181.71%
Net Profit Margin-181.71%
EBITDA Margin-184.84%
EBIT Margin-191.13%
Analyst Forecast
The average price target for Capricor Therapeutics is $43.60, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$43.60
Price Target Upside525.54% Upside
Analyst ConsensusStrong Buy
Analyst Count6
Revenue Growth Forecast-11.55%
EPS Growth Forecast-37.48%